Non‐coding RNA LOXL1-AS1 exhibits oncogenic activity in ovarian cancer via regulation of miR‐18b‐5p/VMA21 axis - 14/03/20
pages | 11 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | LOXL1-AS1 is upregulated in ovarian cancer tissues. |
• | LOXL1-AS1 silencing inhibits the growth and aggressive phenotypes of ovarian cancer cell. |
• | MiR-18b-5p suppresses ovarian carcinoma cell by targeting VMA21. |
• | LOXL1-AS1 regulates ovarian cancer cell growth and metastasis via modulating miR‐18b‐5p/VMA21 axis. |
Abstract |
Long non-coding RNAs (lncRNAs) exert critical effects in the process of malignant cancers and lncRNA LOXL1 Antisense RNA 1 (LOXL1-AS1) has been demonstrated to be a pro-oncogene in multiple tumor types. In the current study, we illuminated the precise roles of LOXL1-AS1 in the development of ovarian cancer. LOXL1-AS1 is significantly overexpressed in ovarian carcinoma tissue compared with adjacent non‐cancerous sample. The luciferase reporter gene assay reveals the relationship between LOXL1-AS1 and miR‐18b‐5p, miR‐18b‐5p and its target gene, Vacuolar ATPase Assembly Factor VMA21 (VMA21). Transfection of LOXL1-AS1 siRNA or miR‐18b‐5p mimics inhibits the growth and aggressive phenotypes of SKOV3 and OVCAR3 cell. Furthermore, miR-18b-5p suppresses ovarian carcinoma cell proliferation and metastasis by targeting VMA21 and LOXL1-AS1 regulates ovarian carcinoma cell growth and metastasis through sponging miR‐18b‐5p. These findings suggest that lncRNA LOXL1-AS1 promotes ovarian cancer cell growth, migratory and invasiveness via modulating miR‐18b‐5p/VMA21 axis.
Le texte complet de cet article est disponible en PDF.Keywords : LOXL1-AS1, Ovarian cancer, Migration, Invasion, miR‐18b‐5p
Plan
Vol 125
Article 109568- mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?